Saphnelo
What Saphnelo is used for
Saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite standard therapy.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Saphnelo
- Active substance
- anifrolumab
- Disease area
- Lupus Erythematosus, Systemic
- Medicine group
- Monoclonal antibodies
- ATC code
- L04AG11
- Marketing authorisation holder
- AstraZeneca AB
- Authorised in the EU since
- 2022
Official information
In the USA
Same active substance: Saphnelo
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Saphnelo used for?
Saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite standard therapy.
What is the active substance in Saphnelo?
Saphnelo contains anifrolumab.
Who makes Saphnelo?
The EU marketing authorisation holder is AstraZeneca AB.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU